Orebriton (Ticagrelor)

Ticagrelor, the active ingredient in Orebriton, is a P2Y12 receptor antagonist presented as a tablet for oral use. It reduces the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or a history of myocardial infarction. GNH USA supplies Orebriton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Orebriton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orebriton is a P2Y12 inhibitor that is used in the management of platelet‑driven cardiovascular conditions.

- Acute coronary syndrome: Reduces the risk of cardiovascular death, myocardial infarction and stroke. - Post‑myocardial infarction: Helps prevent recurrent ischemic events. - Chronic coronary artery disease: Decreases the likelihood of thrombotic complications. - Post‑percutaneous coronary intervention (PCI): Lowers the incidence of stent‑thrombosis. - Secondary prevention of atheroscler​sclerotic events : Supports long‑term reduction of cardiovascular risk.

Ticagrelor may produce a range of adverse reactions, from mild to severe.

Common Side Effects: - Dyspnea : Short  short  short  short  short … - Headache : Occasion  …  - Nausea : Occ …  - Diarr "); - Ble…. -  ... 

Serious or Rare ");\n-  ");  "  " " " " "" ". - "  ". - ");  ".

The  ");  t  d \